Solid Biosciences GX1001: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and childrenwith Duchenne muscular dystrophy.

Project: Research project

Project Details

StatusActive
Effective start/end date3/20/198/31/50

Funding

  • Solid Biosciences LLC